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This is a comprehensive review of the literature regarding the use of Deutetrabenazine in
treating chorea associated with Huntington’s disease. Unfortunately, treatment has been
limited for many aspects of this neurodegenerative disease. The present investigation
presents the background, evidence, and indications for the use Deutetrabenazine in the
setting of Huntington’s disease. Huntington’s disease is characterized by a variety of
motor, psychiatric, and cognitive symptoms with chorea being one of the more notable
ones. Chorea is a movement disorder present in multiple neurologic diseases that causes
involuntary and irregular muscle movements theorized to be stemming from high
dopamine levels. Deutetrabenazine is thought to function as an inhibitor of the VMAT2
vesicular monoamine transporter resulting in decreased monoamine release, including
dopamine, in the synaptic cleft which has a therapeutic effect in management of chorea.
This drug was approved by the FDA in 2017 with a specific indication for tardive
dyskinesia and choreiform movement in Huntington’s disease. Currently, there is no
definitive treatment for Huntington’s disease. Thus, management is primarily focused on
symptom management with the use of a variety of pharmaceutical agents. Chorea is one
of the many manifestations that significantly alter the quality of life of many patients.
Deutetrabenazine is a promising new option for the treatment of chorea in the setting of
Huntington’s disease. Although studies so far have displayed mixed results, further
research, including head-to-head studies, is necessary to elucidate the true potential of
this drug.

INTRODUCTION
Huntington’s disease (HD) is an autosomal-dominant, progressive neurodegenerative disorder characterized by a
triad of motor, psychiatric and cognitive symptoms that
typically onset in middle-aged individuals, although it can
present on a spectrum of ages depending on the extent of
the cytosine-adenosine-guanine (CAG) repeat mutation in
the huntingtin-encoding gene. Specifically, the age of onset
is inversely related to the number of CAG repeats present
with each subsequent generation being diagnosed at earlier
ages related to the phenomenon of anticipation whereby
the number of repeats is increased in each generation.1 Despite being characterized by the aforementioned triad, HD
is classically associated with chorea, an involuntary and irregularly repetitive movement disorder that flows between
various muscle groups. However, it is critical to note that
chorea is not pathognomonic for HD and can be caused by
a multitude of both genetic and non-genetic etiologies that
requires a careful assessment of medications being used as
well as family history.2 It should be noted that family history may not always be reliable and clinical suspicion war-

rants further follow-up and assessment for Huntington’s
disease.
The onset of HD is typically characterized by imperceptible changes affecting movement and personality that may
be mistaken for manifestations of other psychiatric conditions or dismissed as changes associated with aging.2 As
the disease progresses, these manifestations become more
noticeable and disruptive to daily life. Motor involvement
advances from restlessness or fidgeting to more distinct
motor dysfunction, ranging from distinct chorea to ataxia,
parkinsonism features, or even dysphagia.2,3 The psychiatric component of HD may initially present as increased irritability but will advance to more prominent symptoms of
anxiety, major depression, manic episodes, apathy, and/or
psychoses.1 The severity of these psychiatric presentations
will vary and are often accompanied by the third aspect of
the HD triad, cognitive decline. Impairment of executive
functions involving the frontal lobe are common manifestations and can disrupt tasks such as organizing, planning,
and impaired problem-solving. While long-term memory is
often spared during this progression, patients can suffer
from significant dementia. The onset of cognitive and psy-
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chiatric symptoms often manifest years in advance of an official diagnosis of HD.2,3
Currently, there are no cures for HD despite advances in
the understanding of the pathophysiology of the disease.
Instead, treatment is directed at symptomatic management
and counseling to ensure an enhanced quality of life, not
only for the patient but the family as well. Therapeutics
can be especially helpful in managing severe chorea but
must be used with caution as the disease progresses due
to its associated adverse effects. Historically, tetrabenazine
or neuroleptic agents have been trialed but a newer drug,
deutetrabenazine, received recent approval for use by the
Food and Drug Administration (FDA) and shows significant
upside due to its limited adverse effect profile.4

METHODS
We conducted literature searches using PubMed and Google
Scholar between 2020-2021. Articles were chosen based on
relevance to Deutetrabenazine and its therapeutic effects
on chorea. We selected primary literature as well as clinical
trial studies to reflect the validity of the review. Older articles were included as well to refer to previous background
information.
The PubMed and Google Scholar keywords searched were
as follows: Huntington’s disease, chorea, Deutetrabenazine,
neurodegenerative disease, and HTT gene.

HUNTINGTON’S CHOREA EPIDEMIOLOGY,
PATHOPHYSIOLOGY, RISK FACTORS, AND
PRESENTATION
Huntington’s disease, despite being distributed worldwide,
is more prevalent in certain populations. Specifically, individuals of European descent have the highest prevalence
of HD, ranging from 10 to 13.7 cases per 100,00 whereas
individuals of Asian or African descent have significantly
lower rates of prevalence.1–3 The discrepancy in prevalence
amongst various ethnicities is associated with the average
CAG-repeat size in the HTT gene, with European-descended
individuals having longer repeats than those from other
ethnicities.2,5,6 Symptom onset occurs at earlier ages in
each successive generation due to the instability of the CAG
repeat during replication when exceeding 28 repeats in
length. The majority of these instabilities lead to expansion
of the repeat, thus resulting in anticipation.2
The underlying pathophysiology of HD has not been fully
elucidated; however, a number of mechanisms have been
proposed with a particular emphasis on the dysfunction of
the medium spiny neurons (MSNs) in the striatum.5 The
MSNs diverge into two pathways within the striatum, the
indirect and direct pathways. In the early stages of HD, the
indirect pathway is particularly susceptible to the adverse
effects of the mutant HTT gene, resulting in the characteristic hyperkinetic physical symptom of chorea. As HD
progresses, involvement of the direct pathway occurs with
the manifestation of hypokinetic symptoms such as akinesia and dystonia.6,7 Another region of interest with significance in the pathophysiology of HD is the cerebral cortex,
especially in the earliest stages of the disease, where symp-

toms affect cognitive function more than the physical manifestations that characterize the “manifest” stage. Specific
areas of the cerebral cortex that are affected are associated
with the particular symptoms that patients will experience
during the prodromal stages of their disease.7
As HD is an autosomal dominant disease, there are no
risk factors that influence the likelihood of acquiring the
disease or the severity of symptoms. However, multiple
genome-wide association (GWA) studies have been conducted with the identification of several genes that can
modify the onset of symptoms in the HD course. Specifically, genetic variations found on chromosomes 15 and 8
have been suggested to accelerate the age of onset, with a
particular genetic variant on chromosome 15 being associated with a delay in the age of onset of physical symptoms.6,8
Patients will often remain asymptomatic for many years
with the subtle onset of symptoms often within 10-15 years
prior to the “manifest” of HD.9 These pre-manifest symptoms classically consist of cognitive dysfunction, specifically involving executive function and multitasking. Psychiatric symptoms are also common pre-manifest symptoms
experienced by patients, presenting as anxiety or irritability.2 These initial changes may be so subtle that they go unnoticed by the patient and their family, but as the disease
progresses towards manifest HD, these symptoms progress
and slowly cause dysfunction.10 Subtle motor signs can
manifest during the prodromal stage of HD and correspond
with neurological changes that are detectable using MRI.
These pre-manifest neurological changes correlate with the
pathophysiology of HD, specifically involving MSNs of the
striatum and corticostriatal connections.5,9 Family members may notice restlessness or fidgeting in the patient during the early stage of the disease.
As HD progresses, the severity of the triad of systems
affected: cognitive, psychiatric and the motor will become
more severe. Generalized slowing in cognitive function,
frontal lobe dementia, and impairment of speech and swallowing will become more prominent. Speech dysfunction
will begin with dysarthria but can progress to anarthria as
patients move from the premanifest to manifest stage of
HD. Development of dysphagia carries significant morbidity
and risk for aspiration pneumonia.1,2,6,9 While psychiatric
symptoms do not progress in a similar manner to the cognitive and motor symptoms of HD, suicidal ideation rates do
increase as individuals progress from premanifest to manifest HD, and the risk continues to increase as the extent of
disability increases. One other exception is apathy, which
may progress in severity as a consequence of there being
no specific pharmacologic therapeutic treatments for apathy, in contrast to depression or anxiety.2,6 The progression of motor symptoms correlates with the pathophysiology initially involving MSNs in the indirect striatal pathway
followed by MSNs in the direct striatal pathway. Patients
will initially display hyperkinetic motor symptoms characterized by chorea and as HD progresses, they will develop
hypokinetic symptoms, including bradykinesia, rigidity and
postural impairment.1,6,9,10 This progression of the HD
triad correlates with the progression of loss in activities of
daily living (ADLs) of the patients, first affecting their oc-
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cupation and eventually severely impairing the capacity to
complete basic ADLs.9

CURRENT TREATMENT OF HUNTINGTON’S
CHOREA
Current approaches to the treatment of choreiform movements in Huntington’s Disease is highly varied and depend
on the expertise of the treating physician. Furthermore,
the initial decision to treat is also somewhat contested between experts. Given that chorea appears early during HD
and then tends to attenuate as the disease progresses, most
clinicians avoid treating choreiform movements unless they
are particularly severe or pose a danger to the patient or
caregivers.11 Initially, both first- and second-generation antipsychotics were used to manage chorea in HD.12 The questionable efficacy of the neuroleptics, as well as their significant negative side effect profile, necessitated the discovery
of better pharmacologic therapies to alleviate chorea.12
Newer additions for the treatment of chorea include the
vesicular monoamine transporter (VMAT2) inhibitor tetrabenazine, anti-NMDA drugs such as amantadine, and nonpharmacologic approaches such as deep brain stimulation
(DBS). Each of these options is discussed below.
ANTIPSYCHOTICS

All neuroleptic agents are antagonists of the dopamine receptors in the central nervous system with the exception of
aripiprazole, a partial dopamine receptor agonist.11 These
drugs were historically the first-line treatment for the positive movement symptoms of HD. As chorea is thought to
be a result of an excess of dopamine in the basal ganglia,
antipsychotics were thought to be a reasonable option.13
There have been surprisingly few studies focused on the use
of neuroleptics in the treatment of chorea in HD, most likely
due to the reluctance of pharmaceutical companies to invest in studies that do not yield new therapeutic patents.14
The few trials that exist show a dubious benefit of neuroleptics. Typical antipsychotics such as haloperidol and
fluphenazine have received mixed reviews in chorea reduction but continue to be prescribed by some clinicians. Similarly, the atypical antipsychotics (which carry the benefit of
a milder side effect profile than their first-generation counterparts) have failed to produce strong evidence to support
their use in treating choreiform movements.15 Research has
provided the strongest evidence that olanzapine, risperidone, clozapine, and quetiapine improve choreiform movements in HD. However, the risk of severe side effects such
as agranulocytosis associated with clozapine, as well as the
low affinity of clozapine and quetiapine for dopamine receptors limit their use.16 Regardless of the lack of evidence,
antipsychotics are still an option for patients with HD who
desire a reduction in chorea and are highly favored in patients that have comorbid psychosis.11
TETRABENAZINE

Tetrabenazine (TBZ) was the first drug to earn FDA approval
in the treatment of chorea associated with HD and was the
only drug to have this indication until deutetrabenazine

was approved in 2017. TBZ inhibits VMAT2, leading to reduced monoamine loading into presynaptic vesical.7 The
overall effect is a drop in synaptic levels of monoamines,
particularly dopamine, serotonin, and norepinephrine.16
TBZ revolutionized the treatment of chorea and has the
strongest evidence backing its use.12 The main downside to
TBZ is the side effect profile. TBZ carries a risk of the neuroleptic malignant syndrome and QTc prolongation, also
noted with antipsychotics.12 Of note, the reduction in serotonin may cause a worsening of depressive symptoms and
suicidality, which can both be present already in patients
with HD.16 TBZ received a block box warning for this reason
and is contraindicated in patients who are actively suicidal
or have untreated depression.15 Finally, as it is a newer
treatment, TBZ can be rather costly, removing it as an option for many patients.16
AMANTADINE

Amantadine is a known NMDA receptor antagonist that has
shown useful in treating abnormal movements in Parkinson’s disease. It has also been shown to have effects on
dopaminergic pathways in the brain, although these are not
well understood.15 The effects of amantadine on dopamine
in the central nervous system created hopes that it could be
an effective treatment for chorea in HD. Once again, there
is a paucity of studies looking at amantadine for the treatment of chorea. Studies have shown that choreiform movements are attenuated only with very high doses. These high
doses are associated with a side effect profile that limits the
use of amantadine for chorea treatment.12
DBS

In terms of a non-pharmacological approach, deep brain
stimulation has shown promise in the treatment of chorea
in HD, particularly in refractory cases.15 DBS trials have
shown benefits with targeting the globus pallidus internal,
with short-term as well as a sustained reduction in choreiform movements with minimal adverse effects.17
Many of the other interventions studied showed minimal
or no benefit in treating chorea. Interestingly, the anti-glutamate drug riluzole has been endorsed as beneficial by the
American Academy of Neurology (AAN), however, no definitive studies demonstrate a reduction in choreiform movements.18 Decisions of whether or not to treat chorea and
which treatment route to pursue are a discussion between
the physician, the patient, and caregivers.12

DEUTETRABENAZINE DRUG INFO
Deutetrabenazine (AUSTEDO) received approval in 2017
with an indication for tardive dyskinesia and choreiform
movement in HD. It is manufactured by Teva Pharmaceuticals USA, Inc.19 Deutetrabenazine is the product of deuteration- that is, replacing certain hydrogen atoms with deuterium, an isotope of hydrogen that contains a proton and
a neutron. Austedo is the deuterated form of tetrabenazine,
which is the original drug indicated for the treatment of
chorea.20 Austedo has a molecular weight of 323.46 with a
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pKa of 6.31. Deutetrabenazine comes in oral formulations
of 6, 9, and 12 mg.19
Deutetrabenazine carries a number of reported side effects. Some of the most reported side effects include xerostomia, diarrhea, fatigue, and sedation. While the most
concerning side effect of tetrabenazine was an increase in
suicidal ideation and depression, studies showed that
deutetrabenazine had little to no increase in both depression and suicidal thoughts.16 Given that more studies into
the safety of deutetrabenazine need to be completed,
deutetrabenazine is still not recommended for patients with
active suicidal ideation or a history of untreated depression.19 Deutetrabenazine may also increase the QTc interval, increasing the risk of causing deadly cardiac arrhythmias such as torsades de pointes. Assessment of a patient’s
QTc interval via EKG should be performed before as well as
during treatment with deutetrabenazine, especially if the
patient needs a dose above 24 mg. Deutetrabenazine is also
contraindicated in patients who are taking MAOIs, tetrabenazine, and valentine, as well as those who have liver
impairment.19 While unlikely, it has been reported that
deutetrabenazine carries a risk of inducing neuroleptic malignant syndrome.21
The starting dose of deutetrabenazine in patients with
HD is 6 mg. The dose is an oral administration given once
a day. Doses should be titrated up by 6 mg per week until
symptoms resolve, or side effects become intolerable.19 The
maximum dose of deutetrabenazine is 48 mg per day, which
is given as 24 mg twice per day. The maximum dose is reduced to 36 mg per day in patients who are designated
as poor CYP2D6 metabolizers and those who are taking
strong CYP2D6 inhibitors (such as paroxetine or fluoxetine).21 Deutetrabenazine does not need to be tapered down
in the event of discontinuation and can be restarted at the
current dose should the administration be interrupted for
less than a week. In the event that deutetrabenazine is
stopped for greater than one week, dosages should be retitrated if resumed. It is recommended that deutetrabenazine be taken with food.19

MECHANISM OF ACTION
Deutetrabenazine is the deuterated form of the chorea
treatment drug tetrabenazine. As such, it is hypothesized
that it functions in a similar manner to tetrabenazine. The
exact mechanism of both drugs is not completely understood, but evidence points to a reversible, inhibitory effect
on the vesicular monoamine transporter, VMAT2.22 Functionally, VMAT2 works presynaptically to package the
monoamines (e.g., norepinephrine, serotonin, and
dopamine) into vesicles to be released into the synapse
when an action potential reaches the nerve terminal. By
blocking the action of VMAT2, deutetrabenazine can effectively reduce the levels of monoamines in the synaptic
cleft.23 Levels of monoamines are further reduced due to
the fact that they are rapidly metabolized by monoamine
oxidase (MAO) in the presynaptic neuron when not packaged into vesicles. Inhibiting VMAT2 also reduces the uptake of monoamines back into the presynaptic neuron.24 It
is this decrease in monoamine levels, especially dopamine,

that is thought to be therapeutic in the treatment of chorea
in HD.14
The decrease in monoamine levels in the synaptic cleft
also accounts for deutetrabenazine’s side effect profile. The
potential for increased depression and suicidal ideation is
suggested to be from the decrease in serotonin levels in the
central nervous system. Somnolence, as well as the risk of a
neuroleptic malignant syndrome, are both side effects common to antipsychotics, which antagonize dopamine in the
central nervous system. As deutetrabenazine has a similar
mechanism of action to antipsychotics, these side effects
are anticipated and seen clinically. Of note, many described
adverse risks from deutetrabenazine come from experiences
with the original drug tetrabenazine, and not from dedicated studies of deutetrabenazine.25

PHARMACOKINETICS/PHARMACODYNAMICS
Deutetrabenazine has a chemical structure similar to the
drug tetrabenazine, however, there are six atoms of deuterium in place of hydrogen, three on carbon 9 and two on
carbon 10.25 The effects of deuteration is the stabilization
of the molecule while retaining its reactivity.26 Deutetrabenazine is extensively absorbed after oral administration,
with at least 80% of the drug being taken up.19 It is quickly
metabolized in hepatic microsomes by carbonyl reductase
to produce two main active metabolites: α-HTBZ and βHTZB that antagonize VMAT2 in the central nervous system. Peak concentrations of the active metabolites are
reached between three and four hours after administration.
According to radioactive studies, both active metabolites
are extensively distributed to the brain and reach their
highest concentrations in the striatal tissue; the lowest concentrations were found in the cortex. The active metabolites
are mainly biotransformed by the liver enzyme CYP2D6 via
glucuronidation, oxidation, and sulfation; ultimately, they
are excreted by the kidneys.25
The effects of deuteration on the pharmacokinetics of
deutetrabenazine are interesting, and they show promise
that deuteration can be used to improve many current pharmacological treatments in any number of disorders. In addition to the stabilization of the molecule, deuteration creates a drug that is more resistant to metabolism by the
body.27 This is thought to be the result of the fact that
the carbon-deuterium bond is much stronger than the carbon-hydrogen bond: studies show it is around eight times
stronger.25 The resulting effect is that the breakdown of the
active metabolites by the CYP2D6 enzyme is slowed. Interestingly, the strategic placement of the deuterium atoms
in the molecule leads to no effect on the reduction of
deutetrabenazine into the active metabolites, α-HTBZ and
β-HTBZ.27 As a result, studies showed that the half-life of
the active metabolites was doubled with deutetrabenazine
as compared to tetrabenazine, with no increase in peak
plasma concentrations of active metabolites.25 As this
points to an increase in exposure time to active metabolites,
evidence suggests the possibility that deutetrabenazine can
provide the same therapeutic benefit as tetrabenazine with
a lower dose.28 In addition, the increased half-life of active
metabolites results in a twice-a-day dosing for deutetrabenazine compared to thrice-a-day dosing for tetra-
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benazine.26 Given the dose-dependent side effect profile of
both drugs and the difficulties in adherence to a schedule of
multiple doses per day, deutetrabenazine shows promise as
a better alternative for chorea treatment.

CLINICAL STUDIES: SAFETY AND EFFICACY
The clinical effectiveness of Deutetrabenazine as a treatment for chorea among patients with Huntington’s Disease
(HD) was evaluated in a randomized, double-blind, placebocontrolled, parallel-group study done by the Huntington
Study Group known as First-HD. This study took place at
34 sites in the United States and Canada and consisted of
90 patients randomized into two groups. Patients that had
a baseline score of 8 or greater for total maximal chorea
(TMC) of the Unified Huntington Disease Rating SCALE
(UHDRS) and a screening score of 5 or greater for UHDRS
total functional capacity. The TMC score relates to the
severity of chorea, with higher scores equating with more
severe cases of chorea in patients with HD. Patients suffering from serious un/undertreated psychiatric illnesses were
excluded, however, patients on a successful maintenance
dose of medication for psychiatric illnesses such as depression were still included. Patients with a history of suicidal
thoughts or behaviors were excluded. Conditions that also
excluded patients from this study included a prolonged QTc
interval as well as patients taking medication potentially
able to prolong the QT interval, left bundle branch block,
hepatic impairment, renal impairment, as well as patients
who received a score of 11 and higher on the Swallowing
Disturbance Questionnaire. Patients were randomized 1:1
with Half of the patients, n= 45, given deutetrabenazine and
the other group, n=45, of patients receiving the placebo.
The time span of the study was 12 weeks, the first 8 weeks
consisting of a dose-titration period and the remaining 4
weeks being a maintenance phase. Endpoints chosen as
measures of primary efficacy were changes in TMC score
from baseline during the maintenance phase. Secondary efficacy endpoints consisted of 3 parts, the Patient Global Impression of Change (PGIC) score, the Clinical Global Impression of Change (CGIC) score, and a 36-item Short-Form
Health Survey (SF-36) physical functioning subscale score.
Safety Outcomes were measured through changes from
baseline to the end of the maintenance phase. These included the Barnes Akathisia Rating Scale, Epworth Sleepiness Scale, UPDRS speech score, Montreal Cognitive Assessment, HADS depressions, and anxiety subscale. This
study was not designed to investigate adverse events and as
such further investigation is needed to draw more definitive
conclusions on the safety of deutetrabenazine.29 As compared to placebo from baseline to maintenance, patients in
the deutetrabenazine group had a mean of -4.4 (95% CI) improvement in TMC score versus a mean of -1.9 (95% CI) improvement in TMC score in the placebo group with a significant treatment difference of -2.5 (95%CI, p<0.001).30
The same group that performed the FIRST-HD Trial, the
Huntington Group, as well as the Alternatives for Reducing
Chorea in Huntington Disease investigators (ARC-HD) performed another study evaluating the safety of converting
from tetrabenazine to deutetrabenazine for the treatment
of chorea. This was a small open-label, single-arm study

that enrolled 37 patients (n=37) from sites in the United
States and Australia. Patients participating in the study had
received therapeutic relief from the doses of tetrabenazine
they were already prescribed. The patients were then
switched to deutetrabenazine therapy overnight and titration of deutetrabenazine doses occurred weekly after the
first week to optimize control of the chorea. Initially, the
median daily dose of deutetrabenazine was 18mg, and after
adjustments the median dose at week 4 was 30mg and 36mg
at week 8. They evaluated changes from baseline in patient’s Unified Huntington Disease Rating Scale (UHDRS)
total maximal chorea score (TMC) and total motor score
(TMS). Higher scoring indicates more pronounced motor
signs. Safety outcomes were measured as adverse events reported by the patients. Treatment emergent adverse events
(TEAEs), include but are not limited to somnolence, falls,
nasopharyngitis, anxiety, diarrhea, constipation, dry
mouth, depression, and irritability. TEAEs occurred in at
least 4% of patients with 54% of patients reporting at least
1 TEAE.31
The study known as AIM-TD was a double-blind, randomized, placebo-controlled, phase 3 trial aimed at assessing the clinical efficacy, safety, and tolerability of fixed
doses of Deutetrabenazine as a treatment for the involuntary movements in patients with tardive dyskinesia. The
involuntary movements seen in tardive dyskinesia may be
more accurately described as chorea, though they also include stereotypy and/or dystonia.32 AIM-TD was conducted
at various participating centers in the United States and
Europe at 75 centers. Participating patients (n=298) were
randomized (1:1:1:1:1) into 4 groups; patients receiving at
least one dose of the placebo (n=74), patients receiving
12mg per day of deutetrabenazine (n=75), patients receiving 24mg per day (n=74), and patients receiving 36mg/day
(n=75). The primary endpoint for efficacy was a change in
the Abnormal Involuntary Movement Scale (AIMS) score
from baseline to week 12. The 36mg per day group had
a treatment difference of -1.9 points of the AIMS score
(95%CI, p=0.001), and the 24 mg per day group had a treatment difference of -1.8 points of the AIMS score (p=0.003)
versus the placebo group with a difference of -1.4 points.
Reported incidence of AEs were similar between placebo
and deutetrabenazine groups. Rates of nervous system adverse events of interest such as akathisia, dyskinesia,
headache, migraine, parkinsonism, sedation, and somnolence were recorded. Patients in the 36mg/day group experienced a proportion of nervous system AEs greater than the
12mg/day and 24mg/day groups which were more similar to
the placebo rates.33
Tetrabenazine has been shown to improve the symptoms
of chorea associated with HD, but the adverse effects associated with tetrabenazine have raised concern amongst
patients and physicians. Adverse events (AE)s include, but
are not limited to, agitation, akathisia, anxiety, coughing,
depression, diarrhea, drowsiness/somnolence, falls, fatigue,
insomnia, nausea, parkinsonism, and vomiting. In a retrospective study performed by Claassen et. al. unadjusted
and adjusted analyses showed that deutetrabenazine versus
tetrabenazine was associated with a significantly lower risk
of AEs. The researchers utilized data from the First-HD trial
and the TETRA-HD trial and conducted an indirect treat-
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ment comparison of the tolerability of deutetrabenazine
versus tetrabenazine using two anchor-based methods:
Bucher comparison for unadjusted data and matching indirect comparison for adjusted data. Deutetrabenazine
demonstrated significantly lower rates for overall AEs and
moderate to severe AEs than tetrabenazine (p<0.001). The
resulting risk for moderate to severe AEs in the unadjusted
(-39.6%, 95% CI: -67.1, -12.2%; p=0.005) and adjusted
(-46%, 95% CI: -79.4, -13.3%; p=0.006) analyses with
deutetrabenazine compared to tetrabenazine. According to
their analyses, overall dose reductions due to AEs occurred
less frequently with deutetrabenazine as compared with
tetrabenazine before and after adjustment for placebo
(p<0.001).34
Rodrigues et. al compared deutetrabenazine to tetrabenazine indirectly using meta-analytical methods. They
used the results of the TETRA-HD trial and the FIRST-HD
trial, as they considered both studies as methodologically
and clinically similar enough for comparison. Their assessment as to the confidence in the evidence was according
to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working group guidelines.
The indirect comparison according to GRADE showed low
quality evidence that tetrabenazine and deutetrabenazine
do not differ in their clinical efficacy and safety. They found
that deutetrabenazine appeared significantly less likely to
cause somnolence and depressive symptoms, but they cautioned against extrapolating the results of the indirect comparison. No head-to-head randomized blinded trial has
been performed comparing the adverse events related to
deutetrabenazine versus tetrabenazine for the treatment of
HD-related chorea.35
Claassen et. al gave an expert opinion in a review of clinical trial data on Deutetrabenazine for tardive dyskinesia
and chorea associated with HD. They reviewed the clinical efficacy, safety, and pharmacokinetics in Phase III and
long-term extension studies with an emphasis on the longterm safety and tolerability of deutetrabenazine. Their review concluded that regardless of disease severity, deutetrabenazine was tolerated well and effective in long-term
treatment. It highlighted the importance of addressing the
risk of treatment-emergent depression and suicidality.
Providers need to consider the black box warnings for AEs
such as depression and suicide associated with Vesicular
Monoamine Transporter 2 (VMAT2) inhibitors and need to
be carefully monitored for these symptoms. They concluded
that patients with tardive dyskinesia treated with deutetrabenazine had significant reductions in their tardive dyskinesia involuntary movement score.36
Deutetrabenazine’ s pharmacologic properties, drug interactions, administration, and efficacy of administration
was reviewed by Richard et al. As was highlighted by several
reviews, they also noted there are still no direct comparisons between treatments for tardive dyskinesia. The problem remains that no direct head-to-head comparisons of
VMAT2 inhibitors such as tetrabenazine and deutetrabenazine exist. They also conclude both tetrabenazine and
deutetrabenazine administration statistically significantly
improves chorea as compared to placebo and adverse effects
were comparable to placebo.29

Another review evaluating the clinical efficacy and safety
of a deuterated analog of tetrabenazine in the First-HD
study and ARC-HD study by Bashir et al. found that the results from both studies demonstrated that oral deutetrabenazine is generally safe, well-tolerated, and efficacious.25
The main studies investigating deutetrabenazine for the
treatment of chorea are the First-HD clinical trial, the ARCHD clinical trial, and the two indirect comparison studies.
The objective of the First-HD clinical trial was to evaluate
deutetrabenazine versus placebo in the treatment of
chorea. The main conclusion that can be drawn from the
FIRST-HD trial is that it showed a statistically significant
improvement in chorea in patients taking deutetrabenazine
versus placebo. The major drawback of this study was the
lack of head-to-head comparisons of treatment-emergent
adverse events of deutetrabenazine to other VMAT2 inhibitors for the treatment of chorea in HD. The ARC-HD
clinical trial’s objective was to evaluate the safety and efficacy of conversion from tetrabenazine to deutetrabenazine
in an open-label switch overnight from their current dose
to tetrabenazine to deutetrabenazine. This trial found no
worsening symptoms of HD after the overnight conversion
and found a similar side effect profile for deutetrabenazine
when compared with the First HD.
Indirect comparison studies have resulted in conflicting
conclusions on the safety of deutetrabenazine versus tetrabenazine. Claassen et al. performed an indirect comparison
study comparing deutetrabenazine with tetrabenazine with
respect to adverse events. The data was sourced from the
First-HD and Tetra-HD trials. They found an overall lower
risk difference for adverse events with deutetrabenazine
and that there was better medication adherence with
deutetrabenazine compared with tetrabenazine. However,
the results of this indirect comparison have come into question, with concern for lack of clinically meaningful difference versus statistically significant results. The indirect
comparison meta-analysis performed by Rodrigues et al.
compared the tolerability of deutetrabenazine versus tetrabenazine for safety and adverse events. Their meta-analysis
did not demonstrate any differences between the two medications. These authors critique the indirect comparison
study performed by Claassen et al. stating readers should
be aware of the potential for discrepant findings potentially
arising from the rank reversal phenomenon. The metaanalysis suggests that risk differences increase interpretability, but emphasizes odds ratios are the only statistic
able to guarantee to avoid impossible predicted event rates
when extrapolating the data for the population at large.37
Given the dearth of current information directly comparing the clinical efficacy and safety of deutetrabenazine versus other VMAT2 inhibitors, there is a clear need for direct
head-to-head clinical trials. Several clinical reviews comparing the clinical efficacy and safety of deutetrabenazine
versus tetrabenazine as well as an analysis of current literatushowows the need for direct comparison of the medication.15,37–39 While the pharmacokinetics of deutetrabenazine give hope for its reduced toxicity, more
information and direct studies are needed to evaluate the
true long-term safety and efficacy of deutetrabenazine versus other medications.29
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Table 1. Clinical Efficacy and Safety
Author
(Year)

Groups Studied and Intervention

Results and Findings

Conclusions

Frank
et al
(2017)

99 patients with HD randomized to receive
deutetrabenazine or placebo in a double blinded
study

TMC mean scores decreased from
baseline to maintenance
treatment by 4.4 points vs 1.9
points with placebo (P< .001).

Deutetrabenazine
versus placebo
resulted in
improvement of
chorea at 12 week.

37 patients with chorea associated with HD
switched overnight from stable tetrabenazine
regimen to deutetrabenazine. This was an openlabel, single arm study.

Deutetrabenazine was generally
safe and well tolerated. Chorea
scores maintained at week 1 and
improved at week 8.

Chorea scores did not
worsen after the
overnight switch to
deutetrabenazine.
Adverse events and
side effects were like
what was seen in
First-HD

FirstHD
Frank
et al.
(2017)
ARCHD

Table 2. Comparative Studies
Author (Year)

Groups Studied and
Intervention

Results and Findings

Conclusions

Claassen et al.
2017

Indirect comparison
analysis between TetraHD and First-HD.
Comparison between
deutetrabenazine and
tetrabenazine for patient
outcomes and adverse
events

Deutetrabenazine as compared to tetrabenazine
was associated with significantly lower risk of
moderate to severe adverse events (akathisia,
depression, somnolence, insomnia, and
parkinsonism). Deutetrabenazine had
significantly lower rate of dose reduction or
suspension.

Deutetrabenazine
is more tolerable
than
tetrabenazine for
the treatment of
HD associated
chorea.

Indirect comparison using
meta analytical methods.
Tetra-HD and First-HD.
Comparison between
deutetrabenazine and
tetrabenazine for efficacy.

Participants from both groups did not differ
significantly on motor scores or adverse events.

Tetrabenazine
and
deutetrabenazine
do not differ in
efficacy in
reducing motor
scores.

Indirect
tolerability
comparison of
Deutetrabenazine
and
Tetrabenazine for
Huntington
disease
Rodrigues et al.
(2017)
Tetrabenazine
Versus
Deutetrabenazine
for Huntington’s
Disease: Twins or
Distant Cousins?

Providers considering prescribing this medication should
make sure to consult the medication label as there are listed
contraindications and warnings for deutetrabenazine. Contraindications for deutetrabenazine include suicidality, undertreated or untreated depression, hepatic impairment,
and patients current taking monoamine oxidase inhibitors
(MAOI), reserpine, or tetrabenazine. Clinical efficacy and
safety, along with comparative studies are summarized in
Tables 1 and 2.

CONCLUSION
Huntington’s disease is a progressively disabling and ultimately fatal neurodegenerative disorder with autosomal
dominant inheritance. Characterized by a triad of cognitive,
psychiatric, and motor symptoms that largely increase in
severity as the disease progresses, HD can be significantly
disabling for patients. With no definitive cure available,
treatment is directed at symptomatic management to improve the quality of life. Deutetrabenazine, which recently

received FDA approval for the treatment of HD-associated
chorea, is one such therapy. A VMAT-2 inhibitor consisting
of deuterium substituted for hydrogen at various key positions in the tetrabenazine molecule results in a longer halflife and decreased dosing requirements, deutetrabenazine
provides a therapeutic improvement in the severity of
chorea and, subsequently, quality of life. However, there remains a deficit of knowledge regarding the overall efficacy
of deutetrabenazine compared to tetrabenazine. Preliminary meta-analyses of indirect comparison studies have
provided conflicting and inconclusive data, thus necessitating the need for a direct head-to-head study. Nonetheless,
the development of novel therapeutics such as deutetrabenazine offers patients an opportunity to enhance their
quality of life by targeting the disruptive motor symptom of
chorea that is characteristic of HD.
Submitted: December 13, 2021 EDT, Accepted: January 03, 2022
EDT

Health Psychology Research

7

deutetrabenazine for the treatment of chorea associated with Huntington’s disease

REFERENCES
1. Walker RH. Chorea. CONTINUUM.
2013;19:1242-1263. doi:10.1212/01.con.0000436155.4
6909.c3
2. Walker FO. Huntington’s disease. Lancet.
2007;369(9557):218-228. doi:10.1016/s0140-6736(0
7)60111-1
3. Cardoso F. Huntington Disease and Other Choreas.
Neurologic Clinics. 2009;27(3):719-736. doi:10.1016/
j.ncl.2009.04.001
4. Dean M, Sung V. Review of deutetrabenazine: a
novel treatment for chorea associated with
Huntington’s disease. Drug Des Dev Ther.
2018;12:313-319. doi:10.2147/dddt.s138828
5. Snowden JS. The Neuropsychology of Huntington’s
Disease. Arch Clin Neuropsychol. 2017;32(7):876-887.
doi:10.1093/arclin/acx086
6. McColgan P, Tabrizi SJ. Huntington’s disease: a
clinical review. Eur J Neurol. 2018;25(1):24-34. doi:1
0.1111/ene.13413
7. Raymond LA, André VM, Cepeda C, Gladding CM,
Milnerwood AJ, Levine MS. Pathophysiology of
Huntington’s disease: time-dependent alterations in
synaptic and receptor function. Neuroscience.
2011;198:252-273. doi:10.1016/j.neuroscience.2011.0
8.052
8. Lee JM, Wheeler VC, Chao MJ, et al. Identification
of Genetic Factors that Modify Clinical Onset of
Huntington’s Disease. Cell. 2015;162(3):516-526. do
i:10.1016/j.cell.2015.07.003
9. Ghosh R, Tabrizi SJ. Clinical features of
huntington’s disease. In: Advances in Experimental
Medicine and Biology. Springer International
Publishing; 2018:978-973. https://doi.org/10.1007/97
8-3-319-71779-1_1
10. Jankovic J, Roos RAC. Chorea associated with
Huntington’s disease: to treat or not to treat? Mov
Disord. 2014;29(11):1414-1418. doi:10.1002/mds.259
96
11. Coppen EM, Roos RAC. Current Pharmacological
Approaches to Reduce Chorea in Huntington’s
Disease. Drugs. 2017;77(1):29-46. doi:10.1007/s4026
5-016-0670-4

12. Suchowersky O, Armstrong MJ, Miyasaki J.
Evidence-based guideline: pharmacologic treatment
of chorea in Huntington disease: report of the
Guideline Development Subcommittee of the
American Academy of Neurology. Neurology.
2013;80(10):970-970. doi:10.1212/wnl.0b013e318288
5eb3
13. Sung VW, Iyer RG, Gandhi SK, et al. Physician
perceptions of pharmacologic treatment options for
chorea associated with Huntington disease in the
United States. Curr Med Res Opin.
2018;34(4):643-648. doi:10.1080/03007995.2018.1435
518
14. Schmidt C. First deuterated drug approved. Nat
Biotechnol. 2017;35(6):493-494. doi:10.1038/nbt061
7-493
15. Bashir H, Jankovic J. Deutetrabenazine for the
treatment of Huntington’s chorea. Expert Rev
Neurother. 2018;18(8):625-631. doi:10.1080/1473717
5.2018.1500178
16. Wyant KJ, Ridder AJ, Dayalu P. Huntington’s
Disease—Update on Treatments. Curr Neurol Neurosci
Rep. 2017;17(4):1-11. doi:10.1007/s11910-017-0739-9
17. Edwards TC, Zrinzo L, Limousin P, Foltynie T.
Deep brain stimulation in the treatment of chorea.
Mov Disord. 2012;27(3):357-363. doi:10.1002/mds.239
67
18. Reilmann R. Pharmacological treatment of chorea
in Huntington’s disease-good clinical practice versus
evidence-based guideline. Mov Disord.
2013;28(8):1030-1033. doi:10.1002/mds.25500
19. Drugs@FDA: FDA-Approved Drugs. Accessed
December 5, 2021. https://www.accessdata.fda.gov/sc
ripts/cder/daf/index.cfm?event=overview.process&va
rApplNo=209885
20. Schmidt C. First deuterated drug approved. Nat
Biotechnol. 2017;35(6):493-494. doi:10.1038/nbt061
7-493
21. Vesicular Monoamine Transporter 2 (VMAT2)
Inhibitors. LiverTox: Clinical and Research
Information on Drug-Induced Liver Injury. Published
April 2, 2019. Accessed December 5, 2021. https://ww
w.ncbi.nlm.nih.gov/books/NBK548187/
22. Niemann N, Jankovic J. Real-world experience
with VMAT2 inhibitors. Clin Neuropharm.
2019;42(2):37-41. doi:10.1097/wnf.000000000000032
6

Health Psychology Research

8

deutetrabenazine for the treatment of chorea associated with Huntington’s disease

23. Jankovic J. Dopamine depleters in the treatment
of hyperkinetic movement disorders. Expert Opin
Pharmacother. 2016;17(18):2461-2470. doi:10.1080/14
656566.2016.1258063
24. Carvedilol Therapy and CYP2D6 Genotype PubMed. Accessed December 6, 2021. https://pubme
d.ncbi.nlm.nih.gov/30067327/
25. Bashir H, Jankovic J. Deutetrabenazine for the
treatment of Huntington’s chorea. Expert Rev
Neurother. 2018;18(8):625-631. doi:10.1080/1473717
5.2018.1500178
26. Russak EM, Bednarczyk EM. Impact of Deuterium
Substitution on the Pharmacokinetics of
Pharmaceuticals. Ann Pharmacother.
2019;53(2):211-216. doi:10.1177/1060028018797110
27. Schneider F, Bradbury M, Baillie TA, et al.
Pharmacokinetic and Metabolic Profile of
Deutetrabenazine (TEV-50717) Compared With
Tetrabenazine in Healthy Volunteers. Clin Transl Sci.
2020;13(4):707-717. doi:10.1111/cts.12754
28. DeWitt SH, Maryanoff BE. Deuterated Drug
Molecules: Focus on FDA-Approved
Deutetrabenazine. Biochemistry. 2018;57(5):472-473.
doi:10.1021/acs.biochem.7b00765
29. Richard A, Frank S. Deutetrabenazine in the
treatment of Huntington’s disease. Neurodegener Dis
Manag. 2019;9(1):31-37. doi:10.2217/nmt-2018-0040
30. Frank S, Testa CM, Stamler D, et al. Effect of
Deutetrabenazine on Chorea Among Patients With
Huntington Disease: A Randomized Clinical Trial.
JAMA. 2016;316(1):40-50. doi:10.1001/jama.2016.865
5
31. Frank S, Stamler D, Kayson E, et al. Safety of
Converting From Tetrabenazine to Deutetrabenazine
for the Treatment of Chorea. JAMA Neurol.
2017;74(8):977-982. doi:10.1001/jamaneurol.2017.135
2

32. Walker RH. Chorea. CONTINUUM.
2013;19:1242-1263. doi:10.1212/01.con.0000436155.4
6909.c3
33. Anderson KE, Stamler D, Davis MD, et al.
Deutetrabenazine for treatment of involuntary
movements in patients with tardive dyskinesia (AIMTD): a double-blind, randomised, placebo-controlled,
phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. do
i:10.1016/s2215-0366(17)30236-5
34. Claassen DO, Carroll B, de Boer LM, et al. Indirect
tolerability comparison of Deutetrabenazine and
Tetrabenazine for Huntington disease. J Clin Mov
Disord. 2017;4(1). doi:10.1186/s40734-017-0051-5
35. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild
EJ. Tetrabenazine Versus Deutetrabenazine for
Huntington’s Disease: Twins or Distant Cousins? Mov
Disord Clin Pract. 2017;4(4):582-585. doi:10.1002/mdc
3.12483
36. Claassen DO, Philbin M, Carroll B.
Deutetrabenazine for tardive dyskinesia and chorea
associated with Huntington’s disease: a review of
clinical trial data. Expert Opin Pharmacother.
2019;20(18):2209-2221. doi:10.1080/14656566.2019.1
674281
37. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild
EJ. Meta-research metrics matter: letter regarding
article “indirect tolerability comparison of
Deutetrabenazine and Tetrabenazine for Huntington
disease.” J Clin Mov Disord. 2017;4(1):1-3. doi:10.118
6/s40734-017-0067-x
38. Dean M, Sung V. Review of deutetrabenazine: a
novel treatment for chorea associated with
Huntington’s disease. Drug Des Dev Ther.
2018;12:313-319. doi:10.2147/dddt.s138828
39. Rodrigues FB, Wild EJ. Huntington’s Disease
Clinical Trials Corner: February 2018. J Huntington’s
Dis. 2018;7(1):89-98. doi:10.3233/jhd-189001

Health Psychology Research

9

